Table 3.
Characteristics of patients with any events (dose-limiting toxicity or oncologic event).
| #P1 | #P2 | #P3 | #P8 | #P9 | |
|---|---|---|---|---|---|
| Age | 54 | 68 | 51 | 66 | 73 |
| Gender | M | M | M | M | M |
| Tumor site | Larynx | Larynx | Oropharynx | Larynx | Larynx |
| TNM classification | T3N1 | T3N0 | T2N2b | T2N2c | T3N2b |
| Dose olaparib | 25 mg BID | 25 mg BID | 25 mg BDI | 25 mg QD | 25 mg QD |
| Radiation scheme | Accelerated | Accelerated | Accelerated | Conventional | Conventional |
| WHO status before treatment | 0 | 0 | 0 | 0 | 0 |
| ACE-27 score | 2 | 1 | 1 | 2 | 1 |
| Smoking history | 40 pack years | 15 pack years | 30 pack years | 20 pack years | 30 pack years |
| Active smoking at disgnosis | Yes | Yes | Yes | Yes | No |
| Active smoking during treatment | No | No | No | No | No |
| Smoking status after treatment | Resume smoking | Stop | Resume smoking | Stop | Stop |
| DLT | Tracheotomy | Tracheotomy | ORN mandible | No | No |
| Time from end RT to DLT (months) | 5 | 7 | 7 | NA | NA |
| Local and/or regional failure | NED | NED | NED | LRF | RF |
| Time from end RT to failure (months) | NA | NA | NA | 7 | 20 |
| Alive at last follow-up | No | No | No | Yes | Yes |
| Time end RT to death (months) | 52 | 31 | 79 | NA | NA |
Abbreviations: #P1: refer to patient study number; M: male; TNM tumor node metastasis; BID: twice a day; QD: once a day; ACE-27: adult comorbidity evaluation; DLT: dose-limiting toxicity; ORN: osteoradionecrosis; RT: radiotherapy; NA: not applicable; NED: no evidence of disease; LRF: loco-regional failure; RF: regional failure.